A two-drug approach for relapsed or refractory CLL/SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of an oral targeted therapy (nemtabrutinib) followed by a personalized cell therapy (lisocabtagene maraleucel, also called liso-cel) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if this sequence can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of CLL or SLL.
- The disease must be measurable (for example, enlarged lymph nodes, high lymphocyte count, or bone marrow involvement).
- You must be at least 18 years old.
- Your kidney, liver, and heart function should be within acceptable ranges (tests will be done to check).
- You must be able to swallow pills (no feeding tube is allowed).
- You cannot have had certain types of infections, heart rhythm problems, or another cancer that is active.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two targeted oral medications, zanubrutinib and sonrotoclax, for people with CLL or SLL that has come back. The goal is to see if combining them can control the disease better and with fewer side effects than current options.
This Phase 2 trial studies whether combining acalabrutinib and venetoclax can shrink or control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or did not respond to prior treatment. It may help by attacking the cancer using two different medicines together.
This study tests a new oral medication, nemtabrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that did not respond to or stopped responding to certain targeted therapies. The medication aims to control the disease when other options have not worked.
This trial tests a new drug, nemtabrutinib, against two standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment yet. The goal is to see if the new drug works better at controlling the disease.
This clinical trial tests two oral medications, nemtabrutinib and venetoclax, given together to people with untreated CLL or SLL. The goal is to see if this combination effectively kills cancer cells and helps you stay in remission with manageable side effects.
This trial tests a combination of three drugs—nemtabrutinib, venetoclax, and obinutuzumab—for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if this combination is safe and effective in treating the disease.
Hear when a new Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.